Neurological complications after allogeneic hematopoietic stem cell transplantation in children, a single center experience

被引:16
作者
Azik, Fatih [1 ]
Erdem, Arzu Yazal [1 ]
Tavil, Betul [1 ]
Bayram, Cengiz [1 ]
Tunc, Bahattin [1 ]
Uckan, Duygu [1 ]
机构
[1] Ankara Childrens Hematol Oncol Hosp, Dept Pediat Hematol Oncol, Ankara, Turkey
关键词
stem cell transplantation; neurological complication; pediatrics; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE BUSULFAN; REVERSIBLE ENCEPHALOPATHY SYNDROME; CYCLOSPORINE NEUROTOXICITY; SEIZURE PROPHYLAXIS; LEUKOENCEPHALOPATHY; MANIFESTATIONS; RECIPIENTS; CHILDHOOD; DISEASE;
D O I
10.1111/petr.12265
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
In this study, we retrospectively examined the data of children who underwent allo-HSCT from HLA-matched family donors. We analyzed the incidence, etiological factors, clinical characteristics, possible reasons, risk factors, and follow-up of neurologic complications. BU-based conditioning regimens were used in most of the cases (n=62). The median duration of follow-up for the 89 patients was 20months (range 1-41months). Eleven percent of transplanted children developed one or more neurological symptoms after HSCT with a median observation time of twomonths (range -6days to 18months). The median age of the four girls and six boys with neurological complication was 13yr (range 5.3-17.6yr). Cylosporine A neurotoxicity was diagnosed in five children, four of them were PRES. The rest of complications were BU and lorazepam toxicity, an intracranial hemorrhage, a sinovenous thrombosis, and a transient ischemic attack during extracorpereal photopheresis. No difference was found between groups of neurological complication according to age, gender, diagnosis, hospitalization time, neutrophil and platelet engraftment time, stem cell source, and conditioning regimen, acute and chronic GVHD or VOD. Neurological complication was the cause of death in one patient (1.1%).
引用
收藏
页码:405 / 411
页数:7
相关论文
共 26 条
[1]   Posterior leukoencephalopathy syndrome may not be reversible [J].
Antunes, NL ;
Small, TN ;
George, D ;
Boulad, F ;
Lis, E .
PEDIATRIC NEUROLOGY, 1999, 20 (03) :241-243
[2]   Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation [J].
Bartynski, WS ;
Zeigler, ZR ;
Shadduck, RK ;
Lister, J .
NEUROCRITICAL CARE, 2005, 3 (01) :33-45
[3]   Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases [J].
Bleggi-Torres, LF ;
de Medeiros, BC ;
Werner, B ;
Neto, JZ ;
Loddo, G ;
Pasquini, R ;
de Medeiros, CR .
BONE MARROW TRANSPLANTATION, 2000, 25 (03) :301-307
[4]   Lorazepam for seizure prophylaxis during high-dose busulfan administration [J].
Chan, KW ;
Mullen, CA ;
Worth, LL ;
Choroszy, M ;
Koontz, S ;
Tran, H ;
Slopis, J .
BONE MARROW TRANSPLANTATION, 2002, 29 (12) :963-965
[5]   Status epilepticus as a main manifestation of posterior reversible encephalopathy syndrome after pediatric hematopoietic stem cell transplantation [J].
Cordelli, Duccio Maria ;
Masetti, Riccardo ;
Bernardi, Bruno ;
Barcia, Giulia ;
Gentile, Valentina ;
Biagi, Carlotta ;
Prete, Arcangelo ;
Pession, Andrea ;
Franzoni, Emilio .
PEDIATRIC BLOOD & CANCER, 2012, 58 (05) :785-790
[6]   NEUROLOGIC COMPLICATIONS OF BONE-MARROW TRANSPLANTATION [J].
DAVIS, DG ;
PATCHELL, RA .
NEUROLOGIC CLINICS, 1988, 6 (02) :377-387
[7]   Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors [J].
de Brabander, C ;
Cornelissen, J ;
Smitt, PAES ;
Vecht, CJ ;
van den Bent, MJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (01) :36-40
[8]  
Erer B, 1996, BONE MARROW TRANSPL, V18, P157
[9]  
Garrick R, 2000, CLIN BONE MARROW BLO, P958
[10]   Cyclosporine neurotoxicity: a review [J].
Gijtenbeek, JMM ;
van den Bent, MJ ;
Vecht, CJ .
JOURNAL OF NEUROLOGY, 1999, 246 (05) :339-346